Mydrilate (Cyclopentolate Hydrochloride Bp)

Cyclopentolate hydrochloride, the active ingredient in Mydrilate, is an antimuscarinic (anticholinergic) presented as a 0.5% eye drops for ocular use. It produces pupil dilation and temporary paralysis of accommodation, facilitating diagnostic examination and surgical procedures in patients requiring ophthalmic evaluation.

GNH USA supplies Mydrilate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets. The product is manufactured under strict GMP standards and shipped in temperature‑controlled packaging to preserve stability.

Cyclopentolate hydrochloride is a mydriatic/cycloplegic agent used in ophthalmology to achieve pupil dilation and temporary loss of accommodation.

- Ophthalmic examination: provides mydriasis to allow thorough retinal and optic nerve evaluation. - Uveitis or iritis: induces cycloplegia to relieve ciliary spasm, reduce pain and prevent posterior synechiae. - Intraocular surgery: maintains pupil dilation and cycloplegia to facilitate safe intra‑operative access and manipulation. - Diagnostic laser procedures: ensures a stable, dilated pupil for laser photocoagulation or iridotomy. - Anterior segment imaging: stabilizes accommodation to improve accuracy of biometry and corneal topography. - Pediatric eye assessment: provides cycloplegia to facilitate accurate refraction in children.

Cyclopentolate eye drops may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient blurred vision: temporary loss of sharpness that resolves as the drug wears off. - Photophobia: increased sensitivity to light due to pupil dilation. - Mild ocular irritation or burning sensation: brief discomfort on instillation. - Redness of the conjunctiva: mild injection of the eye.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma: sudden rise in intra‑ocular pressure in predisposed eyes, requiring emergency treatment. - Severe allergic reaction (e.g., anaphylaxis, contact dermatitis): signs include swelling, rash, breathing difficulty. - Systemic anticholinergic toxicity (dry mouth, tachycardia, confusion): occurs with excessive absorption, especially in children.

Before using Cyclopentolate eye drops, consider the following precautions to minimize risks and ensure safe administration.

- Assess intraocular pressure before use: avoid in patients with narrow‑angle glaucoma or uncontrolled IOP. - Screen for hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Use with caution in children: systemic absorption is higher, monitor for anticholinergic effects. - Avoid concurrent use with other mydriatics or miotics: may lead to unpredictable pupil response. - Pregnancy and lactation: safety not established; prescribe only when clearly indicated. - Store at ambient temperature: keep in original container, protect from light and moisture.

Cyclopentolate may interact with other ophthalmic or systemic agents; awareness of these interactions helps prevent reduced efficacy or increased adverse effects.

Major Interactions (Avoid): - Other anticholinergic agents (e.g., atropine): additive mydriatic effect may cause excessive pupil dilation. - Miotic agents (e.g., pilocarpine): antagonistic action reduces cyclopentolate efficacy.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers: may alter intraocular pressure dynamics when used together. - Systemic antihistamines or antidepressants with anticholinergic properties: increase overall anticholinergic load. - Intraocular corticosteroids: combined use can elevate intraocular pressure.